Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

The clinical efficacy of Olibanum gum chewing in patients with Mild-to-Moderate Alzheimer disease: A randomized Parallel-Design controlled trial.

  • 2023-12-08
  • Neuropsychopharmacology reports 44(1)
    • Fereshteh Ghorat
    • Mahdi Sepidarkish
    • Farzaneh Saadattalab
    • Maedeh Rezghi
    • Shamim Shahrestani
    • Maryam Gholamalizadeh
    • Saeid Doaei

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 72
Population
72 participants aged 50-75 years with Alzheimer's disease
Methods
Double-blind, randomized clinical trial; intervention group received 1.6 g/day of olibanum chewing gum for 18 weeks, placebo group received chewing gum without olibanum
Blinding
Double-blind
Duration
18 weeks
Funding
Unclear

Background

Alzheimer's disease is a common neurodegenerative disorder in elderly with progressive decline in cognitive functions. This study aimed to investigate the possible memory-improving effects of Olibanum on patients with Alzheimer's disease.

Research design and method

This double-blind, randomized clinical trial was carried out on 72 participants aged 50-75 years. The intervention group (n = 36) received 1.6 g/day of olibanum chewing gum for 18 weeks. The placebo group (n = 36) received chewing gum without olibanum. Neuropsychological assessments were performed at baseline, every 4 weeks, and after 18 weeks of the intervention.

Results

There was no significant difference between (MD: 0.84, 95%CI: -1.10 to 2.78, p = 0.392) at baseline. Both groups had linear improvements over time. There was no significant difference between two groups regarding the improvements after the intervention (F = 0.157, p = 0.693). There were no significant differences between the groups for MMSE score (Mini-Mental State Examination) after the intervention (F = 0.141, p = 0.708).

Conclusions

This study revealed that 18 weeks of gum chewing with Olibanum did not change the neuropsychological status. More clinical studies are needed to confirm these findings.

Research Insights

  • Boswellia→Improved Cognitive Function

    There was no significant difference between two groups regarding the improvements after the intervention (F = 0.157, p = 0.693). There were no significant differences between the groups for MMSE score after the intervention (F = 0.141, p = 0.708).

    Effect
    Neutral
    Effect size
    Small
    Dose
    1.6 g/day
Back to top